Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Development of the First Inner Ear Organoids by 3D Bioprinting for Pharmacological Screening in Hearing Disorders: CTIBIOTECH™ Announces Strategic Agreement With SATT AxLR and CILCARE


      News provided by

      CTIBIOTECH, CILCARE and SATT AXLR

      Oct 10, 2025, 08:48 ET

      Share this article

      Share this article


      LYON, France and MONTPELLIER, France, Oct. 10, 2025 /PRNewswire/ -- CTIBIOTECH™, a leading innovator in human tissue engineering and 3D bioprinting, is proud to announce its selection by SATT AxLR and CILCARE to support the development of the OrgaEar project. This strategic collaboration aims to create a world first: 3D bioprinted inner ear organoids from human induced pluripotent stem cells (hiPSC).

      Continue Reading
      Principle of 3D bioprinting and 3D bioprinter in action
      Principle of 3D bioprinting and 3D bioprinter in action
      Diagram of the human ear, showing the inner ear and cochlea, where the sensory hair cells responsible for converting sound into nerve signals are located
      Diagram of the human ear, showing the inner ear and cochlea, where the sensory hair cells responsible for converting sound into nerve signals are located

      This innovative project addresses a critical need in hearing disorders research by developing advanced pharmacological screening tools, positioned as intermediaries between traditional cell lines and animal models. The aim is to transpose and optimize the previously established protocol for obtaining inner ear organoids by integrating CTIBIOTECH™ 3D bioprinting technology, thus guaranteeing reproducibility, optimal quality and yield, and industrialization in the medium term to contribute to CILCARE's development and business.

      Protocols have been developed by the Bioengineering and Nanosciences Laboratory (LBN) at the University of Montpellier enabling the design and production of inner ear organoids from hiPSCs. The CTIBIOTECH™ teams were selected by SATT AxLR for their unique expertise in 3D bioprinting, the fruit of over 15 years of R&D in human tissue biomanufacturing to facilitate the translation and industrial production of this technology at CILCARE. Having demonstrated its ability to mass-produce complex human skin models - recently including the first computer-connected skin with sensory nervous system - CTIBIOTECH™ will now apply its bioproduction, bio-extrusion additive manufacturing and automation technologies to inner ear organoids. CTIBIOTECH™, by facilitating a highly advanced non-animal NAMs (New Approach Methods) alternative in the hearing disorders sector, strengthens its position at the forefront of a cell-based bioassay market estimated at 28 billion euros by 2028, (CAGR > 7%).

      Professor Colin McGUCKIN, President and Chief Scientific Officer of CTIBIOTECH™, noted: "We are honored to have been selected for this pioneering project. Inner ear organoids represent one of the most sophisticated models in tissue engineering, and we are convinced that our bioprinting automation approach will significantly accelerate research into hearing disorders."

      Dr. Nico FORRAZ, Chief Executive Officer of CTIBIOTECH™, emphasized the strategic importance of this agreement: "Working alongside CILCARE and SATT AxLR, we are helping to develop tools that will accelerate the discovery of treatments for hearing pathologies affecting more than 1 billion people worldwide. This collaboration fits in perfectly with our strategy of reducing drug development costs and time through innovation in automation."

      Hearing disorders are a growing global public health issue. According to the World Health Organization, one in four people will be affected by hearing loss by 2050, and over a billion young people are already at high risk due to unsafe listening practices, notably via the prolonged use of high-volume headphones.

      Beyond the individual impact - on quality of life, mental health, cognitive abilities and social integration - the economic consequences are considerable. The WHO estimates the global cost of unmanaged hearing loss at $980 billion a year, including lost productivity, special education and healthcare costs.

      However, to date, no pharmacological treatment exists to prevent or restore hearing loss. Hearing aids and implants can improve sound perception, but do not target the biological causes and remain only partially effective, particularly in noisy environments. In this context, the development of innovative therapeutic solutions is an urgent and strategic public health priority.

      The development of 3D bioprinted inner ear organoids represents a major step forward to:

      • Accelerate pharmacological screening: standardized, reproducible models will enable rapid testing of new drug candidates;

      • Reduce animal testing: An ethical and more predictive alternative for research into hearing disorders;

      • Improve clinical relevance: Human organoids offer superior predictive power to traditional mouse models;

      • Industrialize production: 3D bioprinting will enable mass production with consistent quality.

      "Organoids are set to become essential tools in medical research. The research program financed by SATT AxLR and the support of CTIBIOTECH, in this key stage, will enable Cilcare to accelerate the development of new therapeutic solutions and thus become the leader in the treatment of hearing pathologies." - Philippe Nérin President of SATT AxLR

      "Organoids are changing the way we think about preclinical research: they reduce the time needed to discover and validate new therapies, while improving their biological relevance. This is a key step towards faster, more responsible medical innovation," comments Sylvie Pucheu, Director of Preclinical Innovation and co-founder of Cilcare.

      About CTIBIOTECH™

      CTIBIOTECH™ is a biotechnology company specializing in the development of advanced human tissue models for research, drug discovery and cosmetic testing. Using state-of-the-art bioprinting and tissue engineering techniques, CTIBIOTECH creates highly realistic and functional human tissue models that offer superior predictive power and ethical alternatives to traditional testing methods.

      ctibiotech.com

      About CILCARE

      Cilcare is a biotechnology company specializing in hearing sciences, developing cutting-edge solutions for the characterization, diagnosis and treatment of hearing disorders and related diseases. Founded by three visionary female entrepreneurs, the company today brings together a team of 45 international collaborators, supported by a scientific advisory board. Since its creation in 2014, Cilcare has been dedicated to meeting these global challenges by combining an advanced R&D platform, a promising portfolio of drug candidates and the use of artificial intelligence and machine learning to characterize the various forms of hearing loss.

      www.cilcare.com  

      About SATT AxLR

      SATT AxLR is a technology transfer accelerator. It specializes in the maturation and commercialization of innovative projects stemming from public research. It works with most of the public research laboratories located in Occitanie Est, one of the most dynamic regions in France and Europe, with almost 200 laboratories and nearly 11,000 researchers and research staff. Since its creation, SATT AxLR has financed over 200 innovation programs, invested over €80 million, signed more than 220 transfer contracts with companies and supported 150 start-ups.

      www.axlr.com  

      For more information, please contact:

      CTIBIOTECH™

      Dr Nico FORRAZ
      Chief Executive Officer
      CTIBIOTECH™

      Phone +33 6 78 90 38 50

      [email protected]

      www.ctibiotech.com

      SATT AxLR

      Laurent Biasetti 
      Partnership &
      Communication

      Phone +33 6 15 33 01 57

      [email protected]

      www.axlr.com

      CILCARE

      Marie Peytavy,
      Marketing & Communication
      Director

      [email protected]

      www.cilcare.com

       

      SOURCE CTIBIOTECH, CILCARE and SATT AXLR

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.